by RNA | Oct 20, 2016 | Client Success, Valuation Advisory
THE PROBLEM: A development stage biotechnology company (considering an IPO in the near future) entered into a series of financings which required the valuation of components of the financings deemed to be a derivative for financial reporting purposes. THE SOLUTION:... Read More
